These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 26315045)

  • 1. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
    Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
    Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.
    Ra H; Song LD; Choi JA; Jee D
    PLoS One; 2018; 13(10):e0206690. PubMed ID: 30379971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-utility of telemedicine to screen for diabetic retinopathy in India.
    Rachapelle S; Legood R; Alavi Y; Lindfield R; Sharma T; Kuper H; Polack S
    Ophthalmology; 2013 Mar; 120(3):566-573. PubMed ID: 23211635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
    Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
    Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study.
    Kawasaki R; Akune Y; Hiratsuka Y; Fukuhara S; Yamada M
    Ophthalmic Epidemiol; 2015 Feb; 22(1):4-12. PubMed ID: 25517603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore.
    Nguyen HV; Tan GS; Tapp RJ; Mital S; Ting DS; Wong HT; Tan CS; Laude A; Tai ES; Tan NC; Finkelstein EA; Wong TY; Lamoureux EL
    Ophthalmology; 2016 Dec; 123(12):2571-2580. PubMed ID: 27726962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of vitamin therapy for age-related macular degeneration.
    Rein DB; Saaddine JB; Wittenborn JS; Wirth KE; Hoerger TJ; Narayan KM; Clemons T; Sorensen SW
    Ophthalmology; 2007 Jul; 114(7):1319-26. PubMed ID: 17320962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
    Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC; Brown MM; Turpcu A; Rajput Y
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Utility Analysis of Extending Public Health Insurance Coverage to Include Diabetic Retinopathy Screening by Optometrists.
    van Katwyk S; Jin YP; Trope GE; Buys Y; Masucci L; Wedge R; Flanagan J; Brent MH; El-Defrawy S; Tu HA; Thavorn K
    Value Health; 2017 Sep; 20(8):1034-1040. PubMed ID: 28964434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System.
    Ben ÂJ; Neyeloff JL; de Souza CF; Rosses APO; de Araujo AL; Szortika A; Locatelli F; de Carvalho G; Neumann CR
    Appl Health Econ Health Policy; 2020 Feb; 18(1):57-68. PubMed ID: 31674001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC; Zlateva GP; Earnshaw SR; Pleil AM; Graham CN; Brogan AJ; Shah SN; Adamis AP
    Value Health; 2008; 11(4):563-74. PubMed ID: 18179676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.
    Tamura H; Goto R; Akune Y; Hiratsuka Y; Hiragi S; Yamada M
    PLoS One; 2015; 10(7):e0133628. PubMed ID: 26214804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
    Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
    Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.
    Hopley C; Salkeld G; Wang JJ; Mitchell P
    Br J Ophthalmol; 2004 Apr; 88(4):450-4. PubMed ID: 15031152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.